In the last trading session, 1.38 million Stoke Therapeutics Inc (NASDAQ:STOK) shares changed hands as the company’s beta touched 0.93. With the company’s per share price at $12.60 changed hands at $1.08 or 9.37% during last session, the market valuation stood at $667.38M. STOK’s last price was a discount, traded about -39.52% off its 52-week high of $17.58. The share price had its 52-week low at $4.09, which suggests the last value was 67.54% up since then. When we look at Stoke Therapeutics Inc’s average trading volume, we note the 10-day average is 0.66 million shares, with the 3-month average coming to 709.47K.

Analysts gave the Stoke Therapeutics Inc (STOK) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended STOK as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Stoke Therapeutics Inc’s EPS for the current quarter is expected to be -0.54.

Stoke Therapeutics Inc (NASDAQ:STOK) trade information

Instantly STOK was in green as seen at the end of in last trading. With action 28.31%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 14.23%, with the 5-day performance at 28.31% in the green. However, in the 30-day time frame, Stoke Therapeutics Inc (NASDAQ:STOK) is 11.80% up. Looking at the short shares, we see there were 8.75 million shares sold at short interest cover period of 9.5 days.

The consensus price target for the stock as assigned by Wall Street analysts is 26.5, meaning bulls need an upside of 52.45% from its current market value. According to analyst projections, STOK’s forecast low is 18 with 35 as the target high. To hit the forecast high, the stock’s price needs a -177.78% plunge from its current level, while the stock would need to soar -42.86% for it to hit the projected low.

Stoke Therapeutics Inc (STOK) estimates and forecasts

Data shows that the Stoke Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -12.86% over the past 6 months, a 14.71% in annual growth rate that is considerably lower than the industry average of 15.90%. Year-over-year growth is forecast to reach 98.32% up from the last financial year.

Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 4.2M. 4 analysts are of the opinion that Stoke Therapeutics Inc’s revenue for the current quarter will be 2.83M. The company’s revenue for the corresponding quarters a year ago was 2.8M and 4.22M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 49.89%. The estimates for the next quarter sales put growth at -32.99%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -44.06%. The 2025 estimates are for Stoke Therapeutics Inc earnings to increase by 14.75%, but the outlook for the next 5-year period is at -2.32% per year.

STOK Dividends

Stoke Therapeutics Inc is expected to release its next quarterly earnings report in March.

Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 4.67% of Stoke Therapeutics Inc shares while 107.21% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.46%. There are 107.21% institutions holding the Stoke Therapeutics Inc stock share, with SKORPIOS TRUST the top institutional holder. As of 2024-06-30, the company held 23.4474% of the shares, roughly 10.84 million STOK shares worth $146.5 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 11.6963% or 5.41 million shares worth $73.08 million as of 2024-06-30.

Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.61 shares estimated at $20.26 million under it, the former controlled 3.04% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.87% of the shares, roughly 988.96 shares worth around $12.46 million.